255 related articles for article (PubMed ID: 31130370)
1. Four-factor prothrombin complex concentrate dose response relationship with INR for warfarin reversal.
Yohe AS; Livings SE
Am J Emerg Med; 2019 Aug; 37(8):1534-1538. PubMed ID: 31130370
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
[TBL] [Abstract][Full Text] [Related]
3. Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol.
Fuh L; Goldstein JN; Hayes BD
J Thromb Thrombolysis; 2020 Jul; 50(1):217-220. PubMed ID: 31707622
[TBL] [Abstract][Full Text] [Related]
4. Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding.
Smetana KS; Ziemba R; May CC; Erdman MJ; Van Matre ET; Jones GM
J Thromb Thrombolysis; 2019 Apr; 47(3):369-374. PubMed ID: 30460443
[TBL] [Abstract][Full Text] [Related]
5. A new kid on the block: Outcomes with Kcentra 1 year after approval.
Berndtson AE; Huang WT; Box K; Kobayashi L; Godat LN; Smith AM; Weingarten D; Coimbra R
J Trauma Acute Care Surg; 2015 Dec; 79(6):1004-8. PubMed ID: 26488322
[TBL] [Abstract][Full Text] [Related]
6. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
[TBL] [Abstract][Full Text] [Related]
7. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
8. Is there a difference in efficacy, safety, and cost-effectiveness between 3-factor and 4-factor prothrombin complex concentrates among trauma patients on oral anticoagulants?
Mangram A; Oguntodu OF; Dzandu JK; Hollingworth AK; Hall S; Cung C; Rodriguez J; Yusupov I; Barletta JF
J Crit Care; 2016 Jun; 33():252-6. PubMed ID: 27021851
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
[TBL] [Abstract][Full Text] [Related]
11. Use of four-factor prothrombin complex concentrate in the reversal of warfarin-induced and nonvitamin K antagonist-related coagulopathy.
Young H; Holzmacher JL; Amdur R; Gondek S; Sarani B; Schroeder ME
Blood Coagul Fibrinolysis; 2017 Oct; 28(7):564-569. PubMed ID: 28604569
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
[TBL] [Abstract][Full Text] [Related]
13. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
Bitonti MT; Rumbarger RL; Absher RK; Curran LM
J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
[TBL] [Abstract][Full Text] [Related]
14. Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.
Zemrak W; Manuel F; Smith KE; Rolfe S; Hayes T; Trowbridge RL; Carlone B; Seder D
J Thromb Thrombolysis; 2019 Feb; 47(2):263-271. PubMed ID: 30443817
[TBL] [Abstract][Full Text] [Related]
15. High versus low fixed-dose four factor-prothrombin complex concentrate for warfarin reversal in patients with intracranial hemorrhage.
Compton F; Hall J; De Simone N; Usmani A; Sarode R; Burner J
Transfus Apher Sci; 2022 Oct; 61(5):103444. PubMed ID: 35414467
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin.
Kuroski JE; Young S
Am J Emerg Med; 2017 Jun; 35(6):871-874. PubMed ID: 28161220
[TBL] [Abstract][Full Text] [Related]
17. Emergent reversal of vitamin K antagonists: addressing all the factors.
Martin DT; Barton CA; Dodgion C; Schreiber M
Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the dose of three-factor prothrombin complex concentrate in traumatic brain injury patients on warfarin therapy.
Huynh TK; Costello JL; Rebuck JA
Pharmacotherapy; 2014 Mar; 34(3):260-4. PubMed ID: 24338807
[TBL] [Abstract][Full Text] [Related]
19. Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage.
Corio JL; Sin JH; Hayes BD; Goldstein JN; Fuh L
West J Emerg Med; 2018 Sep; 19(5):849-854. PubMed ID: 30202498
[TBL] [Abstract][Full Text] [Related]
20. Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices.
Rimsans J; Levesque A; Lyons E; Sylvester K; Givertz MM; Mehra MR; Stewart GC; Connors JM
J Thromb Thrombolysis; 2018 Aug; 46(2):180-185. PubMed ID: 29785470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
